Ideally, trials with BRAF and /or MEK inhibitors, or other combinations, will be performed in the future, but due to the rarity of STS and the rarity of the BRAF mutation in STS, this will be extremely difficult. This evidence concerns the gene MAP2K7 and telomere syndrome.